BridgeBio Oncology Therapeutics CEO Pedro Beltran sells $3,442.67 in common shares
BBOT•President and CEO Pedro Beltran sold 1,870 shares on Nov. 18, 2026, at $1.841 per share, leaving him with 41,659 shares held directly.
BBOT•President and CEO Pedro Beltran sold 1,870 shares on Nov. 18, 2026, at $1.841 per share, leaving him with 41,659 shares held directly.
Pedro Beltran, president and CEO of BridgeBio Oncology Therapeutics, sold 1,870 common shares on Nov. 18, 2026, at a reported price of $1.841 per share. He held 41,659 shares directly after the sale.